CD8A and neoplasm: Inhibitors of the immune checkpoint PD‐1/PD‐L1 axis disrupt the interaction between PD‐1 on T cells and PD‐L1 on tumor or stromal cells, augmenting the antitumor activity of CD8+ cytotoxic T lymphocytes (CTLs) [4].